the phenome is the complete set of measurable traits and characteristics that result from the interaction between an individual’s genes, environment, and lifestyle.
It all began in San Diego, USA with a vision to advance personalised diagnostics and treatment technologies through cutting-edge methods such as Next-Generation Sequencing (NGS), Mass Spectrometry, Bioinformatics, and Data Mining.
What started as a pioneering effort has grown into a trusted, innovative, and solutions-driven scientific hub, built on the expertise of a dedicated team committed to continuous improvement and clinical excellence.
All testing is performed in laboratories that meet the ISO 15189 standards, ensuring clinical accuracy and global quality benchmarks.
We use only premium-grade consumables from Qiagen, Illumina, Eppendorf, and other validated providers to ensure consistent results.
All data is processed using the DRAGEN Bio-IT Platform (v3.9) for high-speed, high-accuracy variant calling and analysis.
Prof Adil Mardinoglu
Professor Adil Mardinoglu is a leading expert in systems medicine, computational biology, and bioinformatics. He is a Professor of Systems Biology at King’s College London and at KTH Royal Institute of Technology in Sweden, where he leads cross-disciplinary research in host–microbiome interactions. He also directs the Centre for Host-Microbiome Interactions (CHMI) and has published extensively on metabolic modelling and drug repurposing. Professor Mardinoglu has led multiple EU-funded consortia and is actively involved in translating systems-level data into actionable clinical strategies for chronic diseases, including cancer and metabolic disorders.
Prof Leroy Hood
Dr Leroy Hood, recipient of the National Medal of Science in 2011, co-founded the Institute for Systems Biology and served as its first President until 2017. He is one of only twenty scientists elected to all three United States National Academies of Sciences, Engineering, and Medicine. He earned his MD from Johns Hopkins and his PhD from Caltech, where he contributed to the development of technologies that made the Human Genome Project possible.
With more than 850 publications, 36 patents, and 18 honorary degrees, Dr Hood now focuses his work on Alzheimer’s, cancer, and leading a one million patient genome and phenome initiative. His many honours include the Lasker Award, the Kyoto Prize, the Heinz Award, the Russ Prize, and the National Academy of Sciences Award for Chemistry in Service to Society.
Prof Mathias Uhlen
Dr Mathias Uhlen is a world leading scientist in biotechnology, protein science, and precision medicine. A professor at KTH Royal Institute of Technology since 1988, he is the Director of the Human Protein Atlas, a pioneering project mapping all human proteins in cells, tissues, and organs, and he was the Founding Director of SciLifeLab, Sweden’s national research center for life sciences.
Dr Uhlen’s innovations, including affinity based protein engineering, real time DNA sequencing, and large scale proteomics, have transformed life science research worldwide. He is a member of the United States National Academy of Engineering, EMBO, and the Royal Swedish Academy of Sciences, and he has authored more than seven hundred and fifty publications.
Dr Cheng Zhang
Dr. Cheng Zhang is a Senior Lecturer in systems medicine at King’s College London and a Group Leader at SciLifeLab, KTH Royal Institute of Technology. His research bridges computational biology, multi-omics, and translational science, with a focus on digital human models and AI-guided drug discovery.
Dr. Zhang has pioneered techniques integrating metabolic networks with deep learning to predict therapeutic targets. His work supports innovation in personalised medicine and biotechnology development. He also serves as a Scientific Advisor to health-tech companies, contributing scientific rigour and strategic oversight to breakthrough innovation in preventive healthcare.
Dr Saeed Shoaie
Dr. Saeed Shoaie leads the Translational Systems Biology group at King’s College London and has been a BBSRC and EPSRC UKRI fellow since 2018. He is also the Deputy Lead of the MSc in Microbiome programme and specialises in host–microbiome interactions, metabolic modelling, and systems biology.
Dr. Shoaie received his MSc and PhD in engineering and synthetic biology from Chalmers University of Technology in Sweden, under the mentorship of Professor Jens Nielsen. His current work focuses on microbiome-driven disease mechanisms, therapeutic modelling, and developing computational platforms for multi-omics-based health solutions.
Selin Demiroz
Selin Demiroz leads the diagnostics division, overseeing the development and implementation of advanced at-home testing solutions across genomics, microbiome, and molecular health. With a background in neuroscience and a multidisciplinary approach that bridges science, technology, and design, she ensures every product aligns with the company’s mission to make personalised health accessible and actionable.
Her work focuses on integrating multi-omics data with user-friendly digital tools, driving innovation from research to real-world application. Through strategic partnerships and a deep commitment to scientific integrity, Selin plays a key role in shaping the future of precision diagnostics and preventative healthcare.
Tuana Recber
Tuana Recber leads the therapeutics division, overseeing the development of evidence-based solutions that translate advanced molecular and genomic research into practical health applications. With a background in molecular genetics, she integrates scientific rigour with innovative approaches to design interventions that support long-term wellbeing and longevity.
Her work focuses on bridging the gap between diagnostics and personalised treatment, ensuring that insights from genomic and microbiome data evolve into effective therapeutic strategies. Through close collaboration with researchers and clinicians, Tuana drives the company’s mission to create a new standard in precision health.
Phenome Longevity delivers next-generation health solutions to leading hospital groups worldwide. With a focus on advanced self-testing, precision diagnostics, and omics-driven insights, the company now offers its services to internationally recognised healthcare networks, including the prestigious Acibadem Global Healthcare Group.
By combining clinical-grade innovation with scalable tools, Phenome is redefining how institutions can integrate longevity-focused, personalised health solutions into modern care ecosystems.
Today, these experiences have led us to operate as Phenome Longevity, expanding our reach across the UK, Europe, Korea, Turkiye, and beyond, bringing our mission to a truly global stage.
“Our partnership with Phenome Longevity has enhanced our precision health services with advanced multi omics analysis and outstanding data quality. Together, we are delivering more personalised and future focused healthcare solutions.”
— CEO, Acibadem Health Group
